ProPhase Labs (PRPH) Stock Price, News & Analysis

Company Overview

ProPhase Labs, Inc. is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies. The company’s lab services cater to hospitals, clinics and physician practices by providing timely, accurate results that support patient care and public health monitoring. On the therapeutic side, ProPhase Labs markets a portfolio of over-the-counter products designed to relieve symptoms of cold and flu, including nasal inhalers and throat sprays, alongside branded disinfectants and personal care items.

ProPhase Labs also provides contract manufacturing and packaging services for third-party health and wellness companies, overseeing formulation, sterile filling and quality-control testing within its U.S. facilities. Through these integrated offerings, the company serves a broad domestic customer base in the healthcare, retail and institutional markets. Management continues to focus on expanding its diagnostic test menu and consumer product lines, leveraging regulatory expertise and manufacturing capabilities to support future growth.

Key Stats

• Today's Range: $0.13 to $0.15
• 50-Day Range: $0.07 to $0.16
• 52-Week Range: $0.07 to $6.66
• Volume: 31,249 shs
• Average Volume: 312,270 shs
• Market Capitalization: $835.85 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

PRPH Stock Analysis - Frequently Asked Questions

How have PRPH shares performed this year?

ProPhase Labs' stock was trading at $0.4475 at the start of the year. Since then, PRPH stock has decreased by 69.0% and is now trading at $0.1388.

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) posted its quarterly earnings data on Wednesday, November, 19th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.10) by $0.50. The company earned $0.88 million during the quarter, compared to the consensus estimate of $5.69 million. ProPhase Labs had a negative trailing twelve-month return on equity of 482.05% and a negative net margin of 825.01%.
Read the conference call transcript.

When did ProPhase Labs' stock split?

Shares of ProPhase Labs reverse split on the morning of Monday, December 22nd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of ProPhase Labs?

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ProPhase Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProPhase Labs investors own include Meta Platforms (META), Pfizer (PFE), Valero Energy (VLO), Catalyst Pharmaceuticals (CPRX) and Energy Transfer (ET).

Company Calendar

• Last Earnings: 11/19/2025
• Today: 5/05/2026
• Next Earnings (Estimated): 5/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRPH
• CIK: 868278
• Web: www.prophaselabs.com
• Phone: (215) 345-0919
• Fax: 215-345-5920
• Employees: 130
• Year Founded: 1981

Profitability

• EPS (Trailing Twelve Months): ($3.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$53.36 million
• Net Margins: -825.01%
• Pretax Margin: -680.20%
• Return on Equity: -482.05%
• Return on Assets: -88.90%

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 0.14
• Quick Ratio: 0.14

Sales & Book Value

• Annual Sales: $5.06 million
• Price / Sales: 0.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.46 per share
• Price / Book: 0.06

Miscellaneous

• Outstanding Shares: 6,022,000
• Free Float: 5,444,000
• Market Cap: $835.85 thousand
• Optionable: Optionable
• Beta: 0.15